Skip to main content
SpringerLink
Log in
Book cover

Textbook of Angiology pp 979–986Cite as

Vasospastic Syndrome

  • Chapter

Abstract

Vasospastic diseases are peripheral vascular disorders caused by vasospasm, which means a reversible localized or diffuse vasoconstriction of arteries or smaller blood vessels. Vasospastic syndromes include Raynaud’s disease, acrocyanosis, and livedo reticularis. Because the vasospasm is generally a temporary disorder, the ischemia is reversible. In this case, patients with vasospasm may suffer vasospastic attacks without organic devastating changes in the digits. However, the vasospasm can occur as a prolonged disorder with ischemia, which may lead to organic tissue damage. Raynaud’s disease, acrocyanosis, and livedo reticularis each occur in a primary form or secondary to underlying diseases.13-16 Primary cases are usually benign, and patients suffer little permanent ischémic damage, whereas those who experience the disorders secondary to underlying diseases tend to suffer extreme ischémic damage. Any disease or persistent vasoconstrictive stimulus that produces injuries in the blood vessels may elicit a vasospastic syndrome.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. Abrahamian LM, Berke A, Van Voorhees A. Type 1 diabetes mellitus associated with livedo reticularis: case report and review of the literature. Pediatr Dermatol. 1991;8:46–50.

    Article  PubMed  CAS  Google Scholar 

  2. Adee AC. Managing Raynaud’s phenomenon: a practical approach. Am Fam Physician. 1993;47:823–829.

    PubMed  CAS  Google Scholar 

  3. Aikimbaev KS, Oguz M, Ozbek S, Demirtas M, Birand A, Batyraliev T. Comparative assessment of the effects of vasodilators on peripheral vascular reactivity in patients with systemic scleroderma and Raynaud’s phenomenon: color Doppler flow imaging study. Angiology. 1996;47:475–480.

    Article  PubMed  CAS  Google Scholar 

  4. Anderson RP, Morris BA. Acrocyanosis due to imipramine. Arch Dis Child. 1988;63:204–205.

    Article  PubMed  CAS  Google Scholar 

  5. Arpaia G, Cimminiello C, Bellone M, Aloisio M, Rossi F, Bonfardeci G. Need to expand microvascular investigation of patients with Raynaud’s phenomenon of different etiology: clinical patterns of 106 consecutive patients. Int Angiol. 1994;13:15–18.

    PubMed  CAS  Google Scholar 

  6. Asherson RA, D’Cruz D, Hughes GR. Cryoglobulins, anti-cardiolipin antibodies, and livedo reticularis. J Rheumatol. 1992;19:826.

    PubMed  CAS  Google Scholar 

  7. Asherson RA, Mayou SC, Merry P, Black MM, Hughes GR. The spectrum of livedo reticularis and anticardiolipin antibodies. Br J Dermatol. 1989;120:215–221.

    Article  PubMed  CAS  Google Scholar 

  8. Bachmeyer C, Farge D, Gluckman E, Miclea JM, Aractingi S. Raynaud’s phenomenon and digital necrosis induced by interferon-alpha. Br J Dermatol. 1996;135:481–483.

    Article  PubMed  CAS  Google Scholar 

  9. Baethge BA, Sanusi ID, Landreneau MD, Rohr MS, McDonald JC. Livedo reticularis and peripheral gangrene associated with primary hyperoxaluria. Arthritis Rheum. 1988;31:1199–1203.

    Article  PubMed  CAS  Google Scholar 

  10. Baguley E, Asherson RA, Hughes GR. Anticardiolipin antibodies, livedo reticularis, and cerebrovascular accidents in SLE. Ann Rheum Dis. 1988;47:702–703.

    Article  PubMed  CAS  Google Scholar 

  11. Bartelink ML, Wollersheim H, Vemer H, Thomas CM, de Boo T, Thien T. The effects of single oral doses of 17 beta-oestradiol and progesterone on finger skin circulation in healthy women and in women with primary Raynaud’s phenomenon. Eur J Clin Pharmacol. 1994;46:557–560.

    Article  PubMed  CAS  Google Scholar 

  12. Bedarida G, Kim D, Blaschke TF, Hoffman BB. Venodilation in Raynaud’s disease [see comments]. Lancet. 1993;342:1451–1454.

    Article  PubMed  CAS  Google Scholar 

  13. Belch JJ. Raynaud’s phenomenon. Curr Opin Rheumatol. 1989;1:490–498.

    Article  PubMed  CAS  Google Scholar 

  14. Belch JJ. Raynaud’s phenomenon. Curr Opin Rheumatol. 1990;2:937–941.

    Article  PubMed  CAS  Google Scholar 

  15. Belch JJ. Raynaud’s phenomenon. Curr Opin Rheumatol. 1991;3:960–966.

    Article  PubMed  CAS  Google Scholar 

  16. Belch JJ. Raynaud’s phenomenon: its relevance to scleroderma. Ann Rheum Dis. 1991;50(suppl 4):839–845.

    Article  PubMed  Google Scholar 

  17. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13-14): 2229–2238.

    Article  PubMed  CAS  Google Scholar 

  18. Bigby M, McCoy K. Reddish-blue hands and feet: acrocyanosis with atrophy. Arch Dermatol. 1988;124:265–268.

    Article  PubMed  CAS  Google Scholar 

  19. Blockmans D, Beyens G, Verhaeghe R. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol. 1996;15:148–153.

    Article  PubMed  CAS  Google Scholar 

  20. Blockmans D, Vermylen J, Bobbaers H. Nailfold capillaroscopy in connective tissue disorders and in Raynaud’s phenomenon. Acta Clin Belg. 1993;48:30–41.

    PubMed  CAS  Google Scholar 

  21. Bollinger A. Function of the precapillary vessels in peripheral vascular disease. J Cardiovasc Pharmacol. 1985;7(suppl 3):S147–S151.

    Article  PubMed  Google Scholar 

  22. Bolster MB, Maricq HR, Leff RL. Office evaluation and treatment of Raynaud’s phenomenon. Cleve Clin J Med. 1995;62:51–61.

    PubMed  CAS  Google Scholar 

  23. Bottomley W, Goodfield M. A pathogenic role for en-dothelin in Raynaud’s phenomenon? Acta Derm Venereol. 1994;74:433–434.

    PubMed  CAS  Google Scholar 

  24. Bunker CB, Goldsmith PC, Leslie TA, Hayes N, Foreman JC, Dowd PM. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature, and Raynaud’s phenomenon. jBr J Dermatol. 1996;134:399–406.

    Article  PubMed  CAS  Google Scholar 

  25. Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet. 1993;342:80–83.

    Article  PubMed  CAS  Google Scholar 

  26. Campbell PM, LeRoy EC. Raynaud phenomenon. Semin Arthritis Rheum. 1986;16:92–103.

    Article  PubMed  CAS  Google Scholar 

  27. Cardelli MB, Kleinsmith DM. Raynaud’s phenomenon and disease. Med Clin North Am. 1989;73:1127–1141.

    PubMed  CAS  Google Scholar 

  28. Challenor VF. Angiotensin converting enzyme inhibitors in Raynaud’s phenomenon. Drugs. 1994;48:864–867.

    Article  PubMed  CAS  Google Scholar 

  29. Cimminiello C, Arpaia G, Milani M, Uberti T, Rocchini GM, Motta A, Cristoforetti G, Curri SB. Platelet function in patients with acrocyanosis. Vasa. 1987;16:12–15.

    PubMed  CAS  Google Scholar 

  30. Cimminiello C, Arpaia G, Toschi V, Rossi F, Aloisio M, Motta A, Bonfardeci G. Plasma levels of tumor necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud’s phenomenon. Angiology. 1994;45:1015–1022.

    Article  PubMed  CAS  Google Scholar 

  31. Clements PJ. Raynaud’s phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes [editorial]. Curr Opin Rheumatol. 1993;5:749–752.

    Article  PubMed  CAS  Google Scholar 

  32. Coffman JD. Pathogenesis and treatment of Raynaud’s phenomenon. Cardiovasc Drugs Ther. 1990;4(suppl 1):45–51.

    Article  PubMed  Google Scholar 

  33. Coffman JD. Raynaud’s phenomenon: an update. Hypertension. 1991;17:593–602.

    Article  PubMed  CAS  Google Scholar 

  34. Coffman JD. The diagnosis of Raynaud’s phenomenon. Clin Dermatol. 1994;12:283–289.

    Article  PubMed  CAS  Google Scholar 

  35. Coffman JD, Cohen RA. Serotonergic vasoconstriction in human fingers during reflex sympathetic response to cooling. Am J Physiol. 1988;254:H889–893.

    PubMed  CAS  Google Scholar 

  36. Coffman JD, Cohen RA. Plasma levels of 5-hydroxytrypta-mine during sympathetic stimulation and in Raynaud’s phenomenon. Clin Sci (Colch). 1994;86:269–273.

    CAS  Google Scholar 

  37. Copeman PW. Livedo reticularis: signs in the skin of disturbance of blood viscosity and of blood flow. Br J Dermatol. 1975;93:519–529.

    Article  PubMed  CAS  Google Scholar 

  38. Corbin DO, Wood DA, Macintyre CC, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud’s phenomenon. Eur Heart J. 1986;7:165–170.

    PubMed  CAS  Google Scholar 

  39. Creutzig A, Caspary L, Freund M. The Raynaud phenomenon and interferon therapy. Ann Intern Med. 1996;125:423.

    PubMed  CAS  Google Scholar 

  40. Creutzig A, Freund M. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud’s phenomenon: the acute vasodilatory effect is not sustained. J Cardiovasc Pharmacol. 1995;26:388–393.

    Article  Google Scholar 

  41. Davis E. Oscillometry of radial artery in acrocyanosis and cold sensitivity. J Mal Vasc. 1992;17:214–217.

    PubMed  CAS  Google Scholar 

  42. Devos J, Bulcke J, Degreef H, Michielsen B. Sneddon’s syndrome: generalized livedo reticularis and cerebrovascular disease: importance of hemostatic screening. Dermatology. 1992;185:296–299.

    Article  PubMed  CAS  Google Scholar 

  43. Doria A, Ghirardello A, Boscaro M, Viero ML, Vaccaro E, Patrassi GM, Gambari PF. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus: relationship with Raynaud’s phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies, and corticosteroid therapy. Rheumatol Int. 1995;14:207–211.

    Article  PubMed  CAS  Google Scholar 

  44. Drucker CR, Duncan WC. Antiplatelet therapy in atrophie blanche and livedo vasculitis. J Am Acad Dermatol. 1982;7:359–363.

    Article  PubMed  CAS  Google Scholar 

  45. Englert HJ, Loizou S, Derue GG, Walport MJ, Hughes GR. Clinical and immunologic features of livedo reticularis in lupus: a case-control study. Am J Med. 1989;87:408–410.

    Article  PubMed  CAS  Google Scholar 

  46. Feldaker M, Hines EA Jr., Kierland RR. Livedo reticularis with ulcérations. Circulation. 1956;13:196–216.

    Article  PubMed  CAS  Google Scholar 

  47. Fleischer AJ, Resnick SD. Livedo reticularis. Dermatol Clin. 1990;8:347–354.

    PubMed  Google Scholar 

  48. Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud’s disease. Circulation. 1995;92:1448–1451.

    Article  PubMed  CAS  Google Scholar 

  49. Freedman RR, Mayes MD. Familial aggregation of primary Raynaud’s disease. Arthritis Rheum. 1996;39:1189–1191.

    Article  PubMed  CAS  Google Scholar 

  50. Friedman EI, Taylor LJ, Porter JM. Late-onset Raynaud’s syndrome: diagnostic and therapeutic considerations. Geriatrics. 1988;43:59–63.

    PubMed  CAS  Google Scholar 

  51. Genovese A, Spadaro G, Marone G. Livedo reticularis and congenital hypogammaglobulinemia. J Med. 1992;23:78–80.

    PubMed  CAS  Google Scholar 

  52. Genovese A, Spadaro G, Marone G. Livedo reticularis in a patient with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Dermatol. 1993;18:159–161.

    Article  PubMed  CAS  Google Scholar 

  53. Gjorup T, Kelbaek H, Hartling OJ, Nielsen SL. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud’s phenomenon. Am Heart J. 1986;111:742–745.

    Article  PubMed  CAS  Google Scholar 

  54. Grassi W, Blasetti P, Core P, Cervini C. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1994;33:139–141.

    Article  PubMed  CAS  Google Scholar 

  55. Greenstein D, Gupta NK, Martin P, Walker DR, Rester RC. Impaired thermoregulation in Raynaud’s phenomenon. Angiology. 1995;46:603–611.

    Article  PubMed  CAS  Google Scholar 

  56. Gross AS, Thompson FL, Arzubiaga MC, Graber SE, Hammer RD, Schulman G, Ellis DL, King LJ. Heparin-associated thrombocytopenia and thrombosis (HATT) presenting with livedo reticularis. Int J Dermatol. 1993;32:276–279.

    Article  PubMed  CAS  Google Scholar 

  57. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin, and markers of fibrinolysis in primary Raynaud’s phenomenon and systemic sclerosis. Ann Rheum Dis. 1996;55:122–127.

    Article  PubMed  CAS  Google Scholar 

  58. Hirschl M, Kundi M. Initial prevalence and incidence of secondary Raynaud’s phenomenon in patients with Raynaud’s symptomatology. J Rheumatol. 1996;23:302–309.

    PubMed  CAS  Google Scholar 

  59. Hoogenberg K, Tupker RA, van Essen LH, Smit AJ, Kallen-berg CG. Successful treatment of ulcerating livedo reticularis with infusions of prostacyclin. Br J Dermatol. 1992;127:64–66.

    Article  PubMed  CAS  Google Scholar 

  60. Ishikawa M, Okada J, Shibuya A, Kondo H. CRST syndrome (calcinosis cutis, Raynaud’s phenomenon, sclero-dactyly, and telangiectasia) associated with autoimmune hepatitis. Intern Med. 1995;34:6–9.

    Article  PubMed  CAS  Google Scholar 

  61. Jaffe IA. Serotonin reuptake inhibitors in Raynaud’s phenomenon. Lancet. 1995;345:1378.

    Article  PubMed  CAS  Google Scholar 

  62. Jura E, Palasik W, Meurer M, Palester CM, Czlonkowska A. Sneddon’s syndrome (livedo reticularis and cerebrovascular lesions) with antiphospholipid antibodies and severe dementia in young men: a case report. Acta Neurol Scand. 1994;89:143–146.

    Article  PubMed  CAS  Google Scholar 

  63. Kahaleh B, Matucci CM. Raynaud’s phenomenon and scleroderma: dysregulated neuroendothelial control of vascular tone. Arthritis Rheum. 1995;38:1–4.

    Article  PubMed  CAS  Google Scholar 

  64. Kahaleh MB. Raynaud’s phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes. Curr Opin Rheumatol. 1994;6:603–606.

    Article  Google Scholar 

  65. Kallenberg CG. Early detection of connective tissue disease in patients with Raynaud’s phenomenon. Rheum Dis Clin North Am. 1990;16:11–30.

    PubMed  CAS  Google Scholar 

  66. Kallenberg CG. Connective tissue disease in patients presenting with Raynaud’s phenomenon alone. Ann Rheum Dis. 1991;50:666–667.

    Article  PubMed  CAS  Google Scholar 

  67. Kalter DC, Rudolph A, McGavran M. Livedo reticularis due to multiple cholesterol emboli. J Am Acad Dermatol. 1985;13:235–242.

    Article  PubMed  CAS  Google Scholar 

  68. Khan F, Coffinan JD. Enhanced cholinergic cutaneous va-sodilation in Raynaud’s phenomenon. Circulation. 1994;89:1183–1188.

    Article  PubMed  CAS  Google Scholar 

  69. Kingma K, Wollersheim H, Thien T. Raynaud’s phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol. 1995;7:529–534.

    Article  Google Scholar 

  70. Kiowski W, Erne P, Buhler FR. Use of nifedipine in hypertension and Raynaud’s phenomenon. Cardiovasc Drugs Ther. 1990;4(suppl 5):935–940.

    Article  PubMed  Google Scholar 

  71. Kohli M, Bennett RM. Raynaud’s phenomenon as a presenting sign of ovarian adenocarcinoma. J Rheumatol. 1995;22:1393–1394.

    PubMed  CAS  Google Scholar 

  72. La Civita L, Giuggioli D, Del Chicca M, Longombardo G, Pasero G, Ferri C. Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud’s phenomenon. Ann Rheum Dis. 1996;55:331–332.

    Article  PubMed  Google Scholar 

  73. Lally EV. Raynaud’s phenomenon. Curr Opin Rheumatol. 1992;4:825–836.

    PubMed  CAS  Google Scholar 

  74. Lau CS, Khan F, Brown R, McCallum P, Belch JJ. Digital blood flow response to body warming, cooling, and re-warming in patients with Raynaud’s phenomenon. Angiology. 1995;46:1–10.

    Article  PubMed  CAS  Google Scholar 

  75. Lavras CL, Valente CA. Primary biliary cirrhosis (PBC)-CREST (calcinosis, Raynaud’s phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) overlap syndrome complicated by Sjogren’s syndrome and arthritis. Intern Med. 1995;34:451–454.

    Article  Google Scholar 

  76. Leppert J, Ringqvist A, Ahlner J, Myrdal U, Sorensen S, Ringqvist I. Cold exposure increases cyclic guanosine monophosphate in healthy women but not in women with Raynaud’s phenomenon. J Intern Med. 1995;237:493–498.

    Article  PubMed  CAS  Google Scholar 

  77. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer GG. The evolution of Raynaud’s phenomenon: a longterm prospective study. J Rheumatol. 1995;22:2226–2232.

    PubMed  CAS  Google Scholar 

  78. Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Tamburino G. Plasma endothelin-1 concentrations during cold exposure in essential acrocyanosis. Angiology. 1996;47:1033–1038.

    Article  PubMed  CAS  Google Scholar 

  79. Mannarino E, Pasqualini L, Fedeli F, Scricciolo V, Innocente S. Nailfold capillaroscopy in the screening and diagnosis of Raynaud’s phenomenon. Angiology. 1994;45:37–42.

    Article  PubMed  CAS  Google Scholar 

  80. Maricq HR. Capillary abnormalities, Raynaud’s phenomenon, and systemic sclerosis in patients with localized scleroderma. Arch Dermatol. 1992;128:630–632.

    Article  PubMed  CAS  Google Scholar 

  81. Martinez R, Saponaro A, Russo R, Dragagna G, Leopardi N, Santoro L, Martelli E. Effects of sympathetic stimulation on microcirculatory dynamics in patients with essential acrocyanosis: a study using mental stress. Panminerva Med. 1993;35:9–11.

    PubMed  CAS  Google Scholar 

  82. McHugh NJ, Maymo J, Skinner RP, James I, Maddison PJ. Anticardiolipin antibodies, livedo reticularis, and major cerebrovascular and renal disease in systemic lupus erythe-matosus. Ann Rheum Dis. 1988;47:110–115.

    Article  PubMed  CAS  Google Scholar 

  83. Michiels JJ, Abels J, Steketee J, van Vliet H, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102:466–471.

    PubMed  CAS  Google Scholar 

  84. Naldi L, Marchesi L, Locati F, Berti E, Cainelli T. Unusual manifestations of primary cutaneous amyloidosis in association with Raynaud’s phenomenon and livedo reticularis. Clin Exp Dermatol. 1992;17:117–120.

    Article  PubMed  CAS  Google Scholar 

  85. Nielsen PG. Diffuse palmoplantar keratoderma associated with acrocyanosis: a family study. Acta Derm Venereol. 1989;69:156–161.

    PubMed  CAS  Google Scholar 

  86. Ohtsuka T, Yamakage A, Tamura T. Image analysis of nail fold capillaries in patients with Raynaud’s phenomenon. Cutis. 1995;56:215–218.

    PubMed  CAS  Google Scholar 

  87. Olsen N. Centrally and locally mediated vasomotor activities in Raynaud’s phenomenon. Scand J Work Environ Health. 1987;13:309–312.

    Article  PubMed  CAS  Google Scholar 

  88. Paulson GW, Brandt JT. Amantadine, livedo reticularis, and antiphospholipid antibodies. Clin Neuropharmacol. 1995;18:466–467.

    Article  PubMed  CAS  Google Scholar 

  89. Pearce LA, Waterbury LD, Green HD. Amantadine hy-drochloride: alteration in peripheral circulation. Neurology. 1974;24:46–48.

    Article  PubMed  CAS  Google Scholar 

  90. Picascia DD, Pellegrini JR. Livedo reticularis. Cutis. 1987;39:429–432.

    PubMed  CAS  Google Scholar 

  91. Pistorius MA, Planchon B. Raynaud’s phenomenon in systemic lupus erythematosus. Rev Rhum Engl Ed. 1995;62:349–353.

    Google Scholar 

  92. Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud’s phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology. 1994;45:677–686.

    Article  PubMed  CAS  Google Scholar 

  93. Riente L, Marchini B, Dolcher MP, Puccetti A, Bom-bardieri S, Migliorini P. Anti-collagen antibodies in systemic sclerosis and in primary Raynaud’s phenomenon. Clin Exp Immunol. 1995;102:354–359.

    Article  PubMed  CAS  Google Scholar 

  94. Riera G, Vilardell M, Vaque J, Fonollosa V, Bermejo B. Prevalence of Raynaud’s phenomenon in a healthy Spanish population. J Rheumatol. 1993;20:66–69.

    PubMed  CAS  Google Scholar 

  95. Roath S. Management of Raynaud’s phenomenon: focus on newer treatments. Drugs. 1989;37:700–712.

    Article  PubMed  CAS  Google Scholar 

  96. Rumpl E, Neuhofer J, Pallua A, Willeit J, Vogl G, Stampfel G, Platz T. Cerebrovascular lesions and livedo reticularis (Sneddon’s syndrome): a progressive cerebrovascular dis-order? J Neurol. 1985;231:324–330.

    Article  PubMed  CAS  Google Scholar 

  97. Saraux A, Allain J, Guedes C, Baron D, Youinou P, Le Goff P. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752–754.

    Article  PubMed  CAS  Google Scholar 

  98. Sayers RD, Jenner RE, Barrie WW. Transthoracic endoscopic sympathectomy for hyperhidrosis and Raynaud’s phenomenon. Eur J Vasc Endovasc Surg.,1994;8:627–631.

    Article  CAS  Google Scholar 

  99. Seibold JR. Serotonin and Raynaud’s phenomenon. J Cardiovasc Pharmacol. 1985;7(suppl 7):S95–S98.

    Article  PubMed  Google Scholar 

  100. Shealy CN, Weeth JB, Mercier D. Livedo reticularis in patients with Parkinsonism receiving amantadine. JAMA. 1970;212:1522–1523.

    Article  PubMed  CAS  Google Scholar 

  101. Shepherd RF, Shepherd JT. Raynaud’s phenomenon. Int Angiol. 1992;11:41–45.

    PubMed  CAS  Google Scholar 

  102. Singh S, De Trafford J, Baskerville PA, Martin JE Response of digital arteries to endothelium dependent and independent vasodilators in patients with Raynaud’s phenomenon. EurJ Clin Invest. 1995;25:182–185.

    Article  CAS  Google Scholar 

  103. Smith CR, Rodeheffer RJ. Raynaud’s phenomenon: pathophysiologic features and treatment with calcium-channel blockers. Am J Cardiol. 1985;55:154B–157B.

    Article  PubMed  CAS  Google Scholar 

  104. Speight EL, Lawrence CM. Reticulate purpura, cryoglob-ulinaemia, and livedo reticularis. Br J Dermatol. 1993;129:319–323.

    Article  PubMed  CAS  Google Scholar 

  105. Teh LS, Manning J, Moore T, Tully MP, O’Reilly D, Jayson ML Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol. 1995;34:636–641.

    Article  PubMed  CAS  Google Scholar 

  106. ter Borg E, Piersma WG, Smit AJ, Kallenberg CG, Wouda AA. Serial nailfold capillary microscopy in primary Raynaud’s phenomenon and scleroderma. Semin Arthritis Rheum. 1994;24:40–47.

    Article  PubMed  Google Scholar 

  107. Toumbis IE, Cohen PR. Chemotherapy-induced Raynaud’s phenomenon. Cleve Clin J Med. 1994;61:195–199.

    Google Scholar 

  108. Twist DJ. Acrocyanosis in a spinal cord injured patient—effects of computer-controlled neuromuscular electrical stimulation: a case report. Phys Ther. 1990;70:45–49.

    PubMed  CAS  Google Scholar 

  109. Vayssairat M, Baudot N, Gaitz JP. Raynaud’s phenomenon together with antinuclear antibodies: a common subset of incomplete connective tissue disease. J Am Acad Dermatol. 1995;35:747–749.

    Article  Google Scholar 

  110. Weinstein C, Miller MH, Axtens R, Buchanan R, Little-john GO. Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol. 1987;123:596–600.

    Article  PubMed  CAS  Google Scholar 

  111. Weir NU, Snowden JA, Greaves M, DaviesJG. Livedo reticularis associated with hereditary protein C deficiency and recurrent thromboembolism. Br J Dermatol. 1995;132:283–285.

    Article  PubMed  CAS  Google Scholar 

  112. Wesseling H. Drug treatment in Raynaud’s phenomenon. Vasa Suppl. 1987;18:48–53.

    PubMed  CAS  Google Scholar 

  113. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TJ, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199–206.

    PubMed  CAS  Google Scholar 

  114. Wollersheim H, Cleophas T, Thien T. The role of the sympathetic nervous system in the pathophysiology and therapy of Raynaud’s phenomenon. Vasa Suppl. 1987;18:54–63.

    PubMed  CAS  Google Scholar 

  115. Wollersheim H, van Zwieten P. Treatment of Raynaud’s phenomenon. Eur Heart J. 1993;14:147–149.

    Article  PubMed  CAS  Google Scholar 

  116. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern Med. 1994;33:579–582.

    Article  PubMed  CAS  Google Scholar 

  117. Yancey WJ, Edwards NL, Williams RJ. Cryoglobulins in a patient with SLE, livedo reticularis, and elevated level of anticardiolipin antibodies. Am J Med. 1990;88:699.

    Article  PubMed  Google Scholar 

  118. Young PC, Cuozzo DW, Seidman AJ, Benson PM, Sau P, James WD. Widespread livedo reticularis with painful ulcerations. Arch Dermatol. 1995;131:786–788.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Shigeyuki Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keishu Yasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. International College of Angiology, Inc., USA

    John B. Chang MD, FACS, FICA (Chairman, Board of Directors, Director) (Chairman, Board of Directors, Director)

  2. Long Island Vascular Center, 1050, Northern Boulevard, Roslyn, NY, 11576, USA

    John B. Chang MD, FACS, FICA (Chairman, Board of Directors, Director) (Chairman, Board of Directors, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sasaki, S., Yasuda, K. (2000). Vasospastic Syndrome. In: Chang, J.B. (eds) Textbook of Angiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1190-7_80

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1190-7_80

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7039-3

  • Online ISBN: 978-1-4612-1190-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation